Technology

Stryker's LIFEPAK CR2 Defibrillator Launch to Boost MedSurg

Stryker Corporation SYK recently announced the U.S. launch of its newest defibrillation solution, the LIFEPAK CR2 automated external defibrillator ("AED") with LIFELINKcentral AED program manager. This development came on the heels of the company receipt of FDA’s Premarket Approval ("PMA") in February.

This development is likely to fortify Stryker’s hold in the U.S. emergency service products market apart from strengthening its core MedSurg arm.

About LIFEPAK CR2 Defibrillator

The LIFEPAK CR2 defibrillator comes handy during a cardiac emergency and reduces delayed treatment. It features an array of new technology, including an industry-first cprINSIGHT technology that helps improve survival outcomes. The device is also capable of remotely monitoring patient outcomes through Wi-Fi connectivity by providing near real-time email alerts.

Notably, the device was released in Europe and Canada in 2017 and in Japan in 2018.

Some other emergency care products and systems in Stryker’s portfolio are Berchtold F 300, S-Series Equipment Management System, the Teletom and the iSuite Experience.

MedSurg at a Glance

MedSurg products consist of surgical equipment and surgical navigation instruments, endoscopic and communications systems and patient handling and emergency medical equipment.

Notably, the segment is one of the key drivers of Stryker’s top line, contributing a significant 62.1% to net sales in the last reported quarter. The segment’s sales rose 10% organically in the quarter.

Management is also optimistic about a series of products slated to be launched by the unit in 2019.

Market Prospects

Grand View Research projects that the U.S. emergency medical services products market will see a CAGR of 7.2% between 2018 and 2025.

Growing demand for emergency care, rising incidence of trauma, and increasing healthcare spending are among the key trends fueling market growth.

 

Price Performance

Over the past year, shares of Stryker have rallied 19.4% compared with the industry’s 8.3% increase. The current level is also higher than the S&P 500 index’s 8.2% rise.

Key Picks

A few better-ranked stocks in the broader medical space are Penumbra PEN, Wright Medical WMGI and Masimo Corp. MASI, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Penumbra has a long-term earnings growth rate of 20.9%.

Wright Medical’s long-term earnings growth is projected at 11.3%.

Masimo’s long-term earnings are expected to grow 15.6%.

Will you retire a millionaire?

One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”

Click to get it free >>


Click to get this free report

Masimo Corporation (MASI): Free Stock Analysis Report

Penumbra, Inc. (PEN): Free Stock Analysis Report

Stryker Corporation (SYK): Free Stock Analysis Report

Wright Medical Group N.V. (WMGI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Technology Videos

    #TradeTalks: How Will the Role of the Chief Technology Officer Evolve on the Buy-Side?

    Siepe CEO Michael Pusateri joins Jill Malandrino on TradeTalks to discuss how the role of the Chief Technology Officer will evolve on the buy-side.

    Nov 19, 2020

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More